Posttreatment Amyloid Levels and Clinical Outcomes Following Donanemab for Early Symptomatic Alzheimer Disease

Is lower posttreatment amyloid burden in TRAILBLAZER-ALZ 2 associated with Alzheimer disease (AD) clinical benefit?In this secondary analysis of a randomized clinical trial, lower posttreatment amyloid burden was correlated with slower cognitive and functional decline in participants with early symptomatic AD and with decreases in AD-related plasma biomarkers, including phosphorylated tau and glia fibrillary protein.The correlation between posttreatment amyloid level and clinical benefit observed in this trial supports amyloid plaque removal as the mechanism of action for donanemab treatment.

Corresponding Author: Ming Lu, MD, Eli Lilly and Company, 3711 Market Street, Seventh Floor, Philadelphia, PA 19104 (lu@lilly.com).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.